- Home
- SLDB vs DSGN Comparison
SLDB vs DSGN Comparison
Compare SLDB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- DSGN
- Stock Information
- Founded
- SLDB 2013
- DSGN 2017
- Country
- SLDB United States
- DSGN United States
- Employees
- SLDB N/A
- DSGN N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- SLDB Health Care
- DSGN Health Care
- Exchange
- SLDB Nasdaq
- DSGN Nasdaq
- Market Cap
- SLDB 234.8M
- DSGN 208.9M
- IPO Year
- SLDB 2018
- DSGN 2021
- Fundamental
- Price
- SLDB $4.72
- DSGN $3.50
- Analyst Decision
- SLDB Strong Buy
- DSGN Hold
- Analyst Count
- SLDB 10
- DSGN 1
- Target Price
- SLDB $15.10
- DSGN $4.00
- AVG Volume (30 Days)
- SLDB 2.0M
- DSGN 89.5K
- Earning Date
- SLDB 08-12-2025
- DSGN 08-04-2025
- Dividend Yield
- SLDB N/A
- DSGN N/A
- EPS Growth
- SLDB N/A
- DSGN N/A
- EPS
- SLDB N/A
- DSGN N/A
- Revenue
- SLDB N/A
- DSGN N/A
- Revenue This Year
- SLDB N/A
- DSGN N/A
- Revenue Next Year
- SLDB N/A
- DSGN N/A
- P/E Ratio
- SLDB N/A
- DSGN N/A
- Revenue Growth
- SLDB N/A
- DSGN N/A
- 52 Week Low
- SLDB $2.41
- DSGN $2.60
- 52 Week High
- SLDB $10.37
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- SLDB 59.76
- DSGN 36.07
- Support Level
- SLDB $4.49
- DSGN $3.65
- Resistance Level
- SLDB $5.16
- DSGN $4.21
- Average True Range (ATR)
- SLDB 0.41
- DSGN 0.22
- MACD
- SLDB -0.02
- DSGN -0.06
- Stochastic Oscillator
- SLDB 47.37
- DSGN 0.00
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.